title: Release the hounds! Activating the T-cell response to cancer.
authors.affiliation: From the Section of Medical Oncology, Yale University School of Medicine, New Haven, CT (M.S.).
authors.forename: Mario
authors.initials: M
authors.lastname: Sznol
authors.forename: Dan L
authors.initials: DL
authors.lastname: Longo
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003606:Dacarbazine / Q000008:administration & dosage*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; D003606:Dacarbazine